Oxygen-transferable perfluorocarbon compounds having 9 to 11 carbon atoms such as perfluorodecalin, perfluoro(C.sub.3.sub.-5 -alkylcyclohexanes), perfluoro(C.sub.4.sub.-6 -alkyl tetrahydropyrans), perfluoro(C.sub.5.sub.-7 -alkyltetrahydrofurans), perfluoro(C.sub.5.sub.-7 -alkylmorpholins) and perfluoro(C.sub.9.sub.-11 -trialkylamines) are emulsified in a physiologically acceptable aqueous solution such as Ringer's solution by the aid of a phospholipid as emulsifier and a fatty acid of 8 to 22 ca...

Disclosed is a lyophilized preparation of recombinant factor VIII used as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant factor VIII is prepared by performing lyophilization using a mixture comprising 6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic acid as a stabilizer for stabilizing the recombinant factor VIII which exhibits an unstable activity during lyophilization, rather than using human blood derived albumin.

The present invention relates to gene and peptide sequences of a diabetes-specific endogenous retrovirus which is derived from type 1 diabetes patients. In particular, the present invention relates to a whole genome of the diabetes-specific variant of endogenous retrovirus (ERV-9) purified from pancreatic tissues of type 1 diabetes (insulin-dependent diabetes mellitus [IDDM]) patients and its genes and peptide and their sequences, which can be used as a diagnosing reagent for type 1 diabetes and...

The present invention relates to a method of determining the enzymatic activity of blood coagulation factor XIII by using purified fibrin monomer as a substrate of this enzyme. The enzymatic activity is determined by detecting the degree of cross-linking of fibrin monomer formed by the blood coagulation factor XIII and the fibrin monomer free of blood coagulation factor XIII is obtained by washing the preparation with citric acid solution. The present method can be effectively used for the valid...

Human placental hyaluronidase preparation is prepared by extracting hyaluronidase from human placenta with an aqueous alkaline solution, harvesting globulin fraction from the extract, selectively adsorbing hyaluronidase contained in the fraction on an anion exchanger such as DEAE-Cellulose and eluting it, gel-filtrating the eluate, and lyophilizing the filtrate into powder. The hyaluronidase thus obtained has a molecular weight of about 70,000, with isoelectric point of pH 5.2, and enzymatic opt...

A medical appliance suitable for use in direct or indirect contact with blood, such as an artificial valve, artificial blood vessel, blood transfusion set, solution infusion set, or blood bag characterized by being composed of 100 parts by weight of polyvinyl chloride and as plasticizer 50 to 100 parts by weight of thermoplastic polyurethane of the polyester type, said polyurethane having a softening point of about 70.degree.C and giving no spot other than that of the origin at the same position...

Oxygen-transferable perfluorocarbon compounds having 9 to 11 carbon atoms such as perfluorodecalin, perfluoro(C.sub.3-5 -alkylcyclohexanes), perfluoro(C.sub.4-6 -alkyl tetrahydropyrans), perfluoro(C.sub.5-7 -alkyltetrahydrofurans), perfluoro(C.sub.5-7 -alkylmorpholins) and perfluoro(C.sub.9-11 -trialkylamines) are emulsified in a physiologically acceptable aqueons solution such as Ringer's solution by the aid of a phospholipid as emulsifier and a fatty acid of 8 to 22 carbon atoms, alkali metal ...

An extract is derived from a mixture of the bark of the genus Phellodendron and the defatted seed of the genus Croton and has excellent therapeutic activity in treating various disorders of the immune system. The extract is obtained by extracting the mixture with an organic solvent, filtering the resulting mixture to separate a residue, extracting the residue with hot water to obtain a water soluble solution, concentrating the solution under reduced pressure and saturating vapor pressure, and re...

An albumin preparation having a polymer content of not more than 3% by weight based on the serum albumin content and an .alpha..sub.1 -AGP content of not more than a detectable limit based on the serum albumin content, which is prepared by removing a polymer-forming factor from an albumin aqueous solution by, for example, ion exchange separation or affinity chromatography, and subjecting the solution to a heat treatment.

An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.O, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --CN, --NR.sub.3 R.sub.4, --CONR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3, --NHSO.sub.2 R.sub.3 or --SR.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl...